Filter Results
:
(521)
Show Results For
-
All HBS Web
(521)
- People (2)
- News (133)
- Research (127)
- Events (2)
- Multimedia (5)
- Faculty Publications (71)
Show Results For
-
All HBS Web
(521)
- People (2)
- News (133)
- Research (127)
- Events (2)
- Multimedia (5)
- Faculty Publications (71)
- April 2009 (Revised October 2010)
- Case
Bob Beall at the Cystic Fibrosis Foundation
By: Robert Steven Kaplan and Sophie Hood
Bob Beall is the Chief Executive Officer of the Cystic Fibrosis Foundation (CFF). CFF is an extremely successful organization, but Beall has to determine how to manage the organization through the financial crisis of 2008-2009. In this situation, donations are likely...
View Details
Keywords:
Decision Choices and Conditions;
Financial Crisis;
Philanthropy and Charitable Giving;
Governing and Advisory Boards;
Leadership;
Crisis Management;
Nonprofit Organizations
Kaplan, Robert Steven, and Sophie Hood. "Bob Beall at the Cystic Fibrosis Foundation." Harvard Business School Case 409-107, April 2009. (Revised October 2010.)
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process....
View Details
Keywords:
Drug Development;
Drug Discovery;
Drug Trials;
Pharmaceutical Companies;
Pharmaceutical Company;
Pharmaceuticals;
Therapeutics;
Biologics;
Biotech;
Biotechnology;
Biopharmacy Company;
Biochemistry;
Technology Commercialization;
Technology Companies;
Drug Testing;
Startup;
Start-up;
Startups;
Start-ups;
Startup Financing;
Strategic Decision Making;
Strategic Decisions;
Strategic Evolution;
FDA;
Food And Drug Administration;
Clinical Trials;
Disease Management;
Market Attractiveness;
Market Entry;
Market Opportunities;
Health Disorders;
Technological Innovation;
Information Technology;
Commercialization;
Business Startups;
Finance;
Decision Making;
Strategy;
Market Entry and Exit;
Opportunities;
Pharmaceutical Industry;
Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the...
View Details
Keywords:
Financial Crisis;
Entrepreneurship;
Borrowing and Debt;
Venture Capital;
Financial Management;
Investment;
Health Testing and Trials;
Expansion;
Biotechnology Industry;
Pharmaceutical Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
- September 2013 (Revised November 2015)
- Case
Living Proof: Are We a Technology Company or a Beauty Company?
By: Willy Shih
Jon Flint came up with the idea of a science-based beauty company while talking with his hairdresser about the problems with typical hair and skin care products. Together with a small team that included Professor Robert Langer of MIT, he committed to assemble a team... View Details
Keywords:
Hair Care;
Personal Care;
Science-based;
R&D;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Marketing;
Marketing Strategy;
Product Marketing;
Product Positioning;
Science-Based Business;
Business Strategy;
Commercialization;
Corporate Strategy;
Technology Platform;
Expansion;
Beauty and Cosmetics Industry;
United States;
Boston;
Cambridge
Shih, Willy. "Living Proof: Are We a Technology Company or a Beauty Company?" Harvard Business School Case 614-013, September 2013. (Revised November 2015.)
- June 2021
- Case
uBiome
By: Thomas R. Eisenmann and Olivia Graham
uBiome provided clinical tests that sequenced the DNA of human microbiome samples, providing data on health conditions directly to consumers or to prescribing physicians. Founded in 2012, the San Francisco-based startup raised $105 million from top-tier venture capital...
View Details
- June 2013
- Article
Signals across Multiple Networks: How Venture Capital and Alliance Networks Affect Interorganizational Collaboration
By: Umit Ozmel, Jeffrey J. Reuer and Ranjay Gulati
In this paper, we examine the contingent effects of signals generated by different types of networks on new ventures' formation of future strategic alliances. We argue that the signaling value of a given tie in reducing adverse selection is more pronounced when another...
View Details
Ozmel, Umit, Jeffrey J. Reuer, and Ranjay Gulati. "Signals across Multiple Networks: How Venture Capital and Alliance Networks Affect Interorganizational Collaboration." Academy of Management Journal 56, no. 3 (June 2013): 852–866.
- Web
Class Profile - MBA
Industry Consulting Consumer Products / Retail / E-Commerce Financial Services Health Care / Biotech Manufacturing / Industrial / Energy Media / Entertainment / Travel Military Nonprofit / Government / Education Services Technology...
View Details
- February 2006
- Case
Michelle Levene (A)
Michelle Levene discovers that she is pregnant a few days before receiving an offer for her dream job. The new position would require Levene to travel extensively, something she would not be able to do towards the end of the pregnancy and while caring for a newborn....
View Details
Keywords:
Work-Life Balance
Casciaro, Tiziana E., and Victoria Winston. "Michelle Levene (A)." Harvard Business School Case 406-083, February 2006.
- January 2006
- Case
Jack Strang at SequenceLabs
By: Mukti Khaire, John J. Gabarro and Lynda M. Applegate
How can entrepreneur manage his firm if things go wrong despite having a great idea, a solid team, and financial backing? Jack Strang founded a biotech firm with his friend Peter Evans, to develop molecular pathway-based "cures" for metabolic disorders. The idea was...
View Details
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful...
View Details
Keywords:
Decision Choices and Conditions;
Entrepreneurship;
Governing Rules, Regulations, and Reforms;
Health Testing and Trials;
Product Development;
Business and Government Relations;
Business Strategy;
Biotechnology Industry;
Pharmaceutical Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
- August 2010 (Revised January 2013)
- Case
Avi Kremer
By: Joshua D. Margolis and Mark Wetzel
If you were diagnosed with a terminal illness, how would you respond and what would you do with your remaining time? Avi Kremer contemplates four options for how to devote himself 18 months after being diagnosed with ALS. His experience thus far and the choices he...
View Details
Keywords:
Entrepreneurship;
Values and Beliefs;
Health Disorders;
Leadership Development;
Personal Development and Career;
Social Enterprise;
Personal Characteristics
Margolis, Joshua D., and Mark Wetzel. "Avi Kremer." Harvard Business School Case 411-022, August 2010. (Revised January 2013.)
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late...
View Details
Keywords:
Decision Choices and Conditions;
Financial Crisis;
Entrepreneurship;
Health Care and Treatment;
Technological Innovation;
Product Launch;
Product Development;
Research and Development;
Biotechnology Industry;
United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- Web
MS/MBA Biotechnology: Life Sciences - MBA
Biotechnology: Life Sciences Program at Harvard University builds upon students’ existing biotech and life sciences knowledge and equips them with the latest business and scientific insights. This empowers them to lead transformative...
View Details
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed...
View Details
Keywords:
Change;
Decisions;
Product Development;
Research and Development;
Expansion;
Technology;
Biotechnology Industry
Enriquez-Cabot, Juan, Gary P. Pisano, and Gaye Bok. "In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen." Harvard Business School Case 602-122, April 2002.
- Web
FAQs - MBA
Boston’s biotech, research and entrepreneurial ecosystems? What resources did MS/MBA students have and are there opportunities outside the classroom? The MS/MBA Biotech program is part of a larger community of health care interested...
View Details
- 19 May 2009
- First Look
First Look: May 19, 2009
entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September 2008. The...
View Details
Keywords:
Martha Lagace
- Web
Entrepreneurship & Innovation - MBA
ventures. Pagliuca Harvard Life Lab The Pagliuca Harvard Life Lab is a wet laboratory with co-working space for early-stage, high-potential biotech and life science start-ups founded by Harvard students, alumni, faculty, and postdoctoral...
View Details
- 15 Sep 2010
- Working Paper Summaries
From Bench to Board: Gender Differences in University Scientists’ Participation in Commercial Science
- 15 Dec 2009
- First Look
First Look: Dec. 15, 2009
http://cb.hbsp.harvard.edu/cb/product/510037-PDF-ENG Tengion: Bringing Regenerative Medicine to Life Elie Ofek and Polly Ross RibattHarvard Business School Case 510-031 Tengion is a young biotech company that is at the frontier of...
View Details
Keywords:
Martha Lagace
- February 2022
- Case
Leading The UK Vaccine Task Force
By: Amy C. Edmondson and Claudia Pienica
This case describes the first six months of the UK Vaccine Taskforce, under the leadership of Kate Bingham. With a career spent in the private sector as a biotech investor, Bingham’s appointment within the government was considered unusual. The overarching brief given...
View Details
Keywords:
COVID-19;
Vaccine;
Government;
Health Pandemics;
Health Care and Treatment;
Science;
Innovation and Invention;
Groups and Teams;
Leadership;
Decision Making;
Government and Politics;
Health;
Innovation and Management;
Governance;
Change;
Government Administration;
Health Industry;
Financial Services Industry;
Public Administration Industry;
Europe;
United Kingdom
Edmondson, Amy C., and Claudia Pienica. "Leading The UK Vaccine Task Force." Harvard Business School Case 622-079, February 2022.